Teva Pharmaceutical Industries has announced the US launch of its QVAR RediHaler beclomethasone dipropionate HFA MDI, which was approved by the FDA in August 2017 for the treatment of asthma in patients aged 4 years and older. The RediHaler is a breath actuated device and requires no shaking or priming.
The company is discontinuing sales of the previous version of QVAR and says that pricing for QVAR RediHaler will be comparable to the older product.
Teva Executive VP, North America Commercial, Brendan O’Grady said, “QVAR has been an available asthma treatment option for well over a decade, so we are excited by the new technology of QVAR RediHaler that directly addresses an unmet need in the field of asthma management. By merging our breath-actuated inhaler technology with asthma medication, we hope to better serve the needs of the respiratory community and look forward to seeing the adoption of QVAR RediHaler in the coming months.”
Read the Teva press release.
